Padcev-Keytruda combo delivers more positive data in bladder cancernews2026-02-27T15:00:05+00:00February 27th, 2026|Endpoints News|
Lilly’s GLP-1 pill beats Novo’s in diabetes trial, has more side effectsnews2026-02-26T11:30:10+00:00February 26th, 2026|Endpoints News|
Gilead, Merck plan to debut new daily HIV pillsnews2026-02-25T21:01:54+00:00February 25th, 2026|Endpoints News|
UCLA spinout raises $11M to test microbiome-based weight loss therapynews2026-02-24T19:38:18+00:00February 24th, 2026|Endpoints News|
Patient dies in MacroGenics’ cancer study, FDA puts trial on holdnews2026-02-24T15:40:28+00:00February 24th, 2026|Endpoints News|
Abcuro drug fails muscle weakness trial, development to continuenews2026-02-24T15:24:47+00:00February 24th, 2026|Endpoints News|
Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to marketnews2026-02-24T11:37:17+00:00February 24th, 2026|Endpoints News|
QurAlis’ ALS drug sees early positive signal, but questions remainnews2026-02-23T20:44:51+00:00February 23rd, 2026|Endpoints News|
Roche to stop work on bone health treatment for Duchennenews2026-02-23T14:40:19+00:00February 23rd, 2026|Endpoints News|
First test of gene therapy for rare form of autism is underwaynews2026-02-23T14:00:16+00:00February 23rd, 2026|Endpoints News|
